Last updated: September 5, 2026
Eftrenonacog alfa, marketed as Alprolix by Sanofi, is a long-acting recombinant coagulation factor IX Fc fusion protein for hemophilia B. Its commercial value rests on reduced dosing frequency, established prophylaxis use, and durable physician familiarity. The product faces rising pressure from gene therapy, competing extended-half-life factor IX products, nonfactor prophylaxis, and eventual biosimilar competition.
Sanofi acquired Alprolix through its $11.6 billion acquisition of Bioverativ in 2018. The product remains a recurring-revenue asset, but its growth profile has shifted from market expansion to franchise defense and lifecycle management. U.S. biologic exclusivity runs from the 2014 first licensure date, placing the principal BPCIA exclusivity milestone in 2026, subject to statutory extensions and patent-specific rights. (Sanofi, 2018; FDA, 2014)
What is coagulation factor IX recombinant Fc fusion protein?
Eftrenonacog alfa is a recombinant factor IX molecule fused to the Fc region of human immunoglobulin G1. The Fc component uses the neonatal Fc receptor recycling pathway to extend circulating half-life.
| Attribute |
Eftrenonacog alfa |
| Brand |
Alprolix |
| Active ingredient |
Coagulation factor IX recombinant Fc fusion protein |
| Developer at launch |
Biogen and Sobi |
| Current commercial owner |
Sanofi |
| FDA approval |
March 28, 2014 |
| FDA application |
BLA 125444 |
| Therapeutic area |
Hemophilia B |
| Primary use |
On-demand treatment and routine prophylaxis |
| Administration |
Intravenous infusion |
| Commercial differentiation |
Extended half-life |
| U.S. regulatory category |
Reference biologic |
| Primary U.S. patent database |
Purple Book and patent records, not the Orange Book |
Alprolix is approved for the control and prevention of bleeding episodes, perioperative management, and routine prophylaxis in adults and children with hemophilia B. The product is administered less frequently than conventional factor IX products, although the appropriate interval depends on age, pharmacokinetics, bleeding phenotype, and clinical response. (FDA, 2024a)
How does Alprolix compare with competing factor IX products?
Alprolix competes in a market divided between standard half-life factor IX, extended-half-life factor IX, gene therapy, and nonfactor prophylaxis.
| Product |
Manufacturer |
Technology |
Commercial positioning |
| Alprolix |
Sanofi |
Fc fusion |
Extended-half-life factor IX |
| Idelvion |
CSL Behring |
Albumin fusion |
Extended-half-life factor IX |
| Rebinyn |
Novo Nordisk |
GlycoPEGylated factor IX |
Extended-half-life factor IX |
| BeneFIX |
Pfizer |
Standard recombinant factor IX |
Established conventional replacement |
| Rixubis |
Takeda |
Standard recombinant factor IX |
Conventional replacement |
| Ixinity |
Medexus |
Standard recombinant factor IX |
Conventional replacement |
| Hemgenix |
CSL Behring |
AAV gene therapy |
One-time treatment approach |
| Alhemo |
Novo Nordisk |
Nonfactor prophylaxis |
Subcutaneous prophylaxis for selected patients |
Why extended-half-life factor IX remains commercially relevant
The core commercial benefit is lower infusion frequency. Patients who need lifelong replacement therapy may value fewer intravenous administrations, particularly children, adolescents, and patients with difficult venous access.
Extended-half-life products also support individualized prophylaxis. Physicians can adjust dose and interval to maintain factor IX exposure while controlling annualized bleeding rates. Switching barriers include established treatment routines, product-specific pharmacokinetic data, patient preference, payer authorization, and concerns about inhibitor development or loss of bleed control.
Alprolix competes most directly with Idelvion and Rebinyn. The products are not clinically interchangeable solely because each has an extended half-life. Their fusion or chemical modification technologies, dosing conventions, pharmacokinetic profiles, and available clinical data differ.
What is the financial trajectory of Alprolix?
Alprolix has developed from a launch-stage rare-disease product into a mature specialty-care asset. Its financial trajectory has four phases:
- Launch and adoption, 2014-2017. The product established demand among hemophilia B patients seeking longer dosing intervals.
- Ownership transition, 2018. Sanofi acquired Bioverativ and assumed control of Alprolix and the broader hemophilia portfolio.
- Global scale and portfolio integration, 2018-2022. Sanofi expanded its rare-blood-disorder platform and used its commercial infrastructure to support the product.
- Maturity and competitive defense, 2023 onward. Revenue quality remains strong because treatment is chronic, but growth is constrained by gene therapy, competing products, and nonfactor prophylaxis.
What did Sanofi pay for Alprolix?
Sanofi agreed in 2018 to acquire Bioverativ for approximately $11.6 billion, including assumed debt. The transaction gave Sanofi access to Alprolix, Eloctate, and Bioverativ's broader hematology platform. (Sanofi, 2018)
The acquisition price reflected:
- Recurring revenue from lifelong hemophilia treatment.
- High barriers to entry in recombinant coagulation products.
- Global specialty-pharma infrastructure.
- The strategic value of extended-half-life factor technology.
- Pipeline and manufacturing capabilities beyond a single product.
The valuation also embedded long-term lifecycle risk. Alprolix was already commercial at acquisition, so Sanofi paid for an established franchise rather than early-stage clinical optionality.
How does Sanofi report Alprolix revenue?
Sanofi's annual reporting groups products within broader specialty-care and rare-disease categories, and the presentation of product-level financial data can vary by reporting period. Alprolix is economically important because it produces recurring treatment revenue, but it does not have the growth profile of Sanofi's largest immunology products.
The principal financial indicators are:
| Financial driver |
Effect on Alprolix |
| Chronic treatment duration |
Supports recurring demand |
| Extended dosing interval |
Supports premium positioning |
| Hemophilia B prevalence |
Limits total addressable population |
| Global reimbursement |
Determines realized net price |
| Gene therapy adoption |
Creates substitution risk |
| Product switching |
Can preserve or erode share |
| Manufacturing reliability |
Protects supply continuity |
| Biosimilar entry |
Could pressure price and volume |
The asset's revenue trajectory is likely to be relatively resilient but increasingly flat in mature markets. Growth opportunities remain in underdiagnosed patients, emerging markets, pediatric prophylaxis, and conversion from standard half-life factor IX. The largest downside risk is not abrupt generic erosion. It is gradual displacement by gene therapy and nonfactor treatment in eligible patients, combined with payer pressure on factor replacement pricing.
When does Alprolix lose regulatory exclusivity?
Alprolix received FDA approval in March 2014. Under the Biologics Price Competition and Innovation Act, a reference biologic generally receives 12 years of reference-product exclusivity from first licensure. The principal U.S. exclusivity date therefore falls in 2026. (FDA, 2014; 42 U.S.C. § 262)
| Milestone |
Date |
| FDA approval |
March 28, 2014 |
| Expected 12-year reference-product exclusivity milestone |
March 28, 2026 |
| Orphan-drug exclusivity |
Expired before the 2026 biologic milestone |
| Patent protection |
Depends on individual patent claims, terminal disclaimers, adjustments, and litigation |
| First possible biosimilar approval |
Dependent on FDA application timing, patent litigation, and exclusivity analysis |
Reference-product exclusivity does not automatically establish a commercial launch date for a biosimilar. A biosimilar applicant must still satisfy FDA requirements, address patent disputes, and comply with applicable notice and approval rules.
What is the Orange Book status of Alprolix?
Alprolix is a biologic, so its principal regulatory listing is in the FDA's Purple Book rather than the Orange Book. The Orange Book is primarily used for approved small-molecule drugs and their listed patents and exclusivity.
For Alprolix, the relevant legal review should include:
- FDA Purple Book reference-product status.
- BLA 125444 regulatory history.
- U.S. patent assignments and continuations.
- Patent-term adjustment and patent-term extension records.
- Any patent certifications or litigation involving a biosimilar applicant.
- Manufacturing and process patents that may not be publicly linked in a single Orange Book-style list.
What patents protect Alprolix and the Fc-fusion technology?
Alprolix is protected through a layered intellectual-property estate rather than one exclusive product patent. The relevant categories include:
| Patent category |
Protected subject matter |
Commercial significance |
| Composition patents |
Factor IX-Fc molecules and sequence variants |
Direct product protection |
| Fusion-architecture patents |
Fc linkage, hinge regions, and molecular configuration |
Limits design-around options |
| Formulation patents |
Stability, concentration, buffers, and storage |
Supports product presentation |
| Manufacturing patents |
Cell culture, purification, and processing |
Raises entry and scale-up barriers |
| Use patents |
Prophylaxis, bleeding control, and dosing regimens |
Can affect launch strategy |
| Platform patents |
FcRn-mediated half-life extension |
May cover related biologics beyond Alprolix |
The strongest protection is generally the combination of molecule-specific claims, manufacturing know-how, regulatory exclusivity, and commercial scale. A biosimilar developer may be able to design around an expired platform patent while still facing the practical burden of reproducing a complex recombinant Fc-fusion protein.
A patent expiration date should be assessed claim by claim. Filing date, patent-term adjustment, patent-term extension, continuation practice, terminal disclaimers, and enforceability can produce different effective dates for different patents. The 2026 regulatory exclusivity milestone is therefore not the same as the end of all intellectual-property protection.
Are there Paragraph IV challenges to Alprolix?
Paragraph IV challenges apply to abbreviated new drug applications for small-molecule drugs under the Hatch-Waxman system. Alprolix is a biologic, so a biosimilar applicant generally proceeds under the BPCIA rather than filing a conventional Paragraph IV certification against an Orange Book listing.
The relevant biosimilar sequence is:
- Submission of a biosimilar application under section 351(k).
- Exchange of manufacturing and patent information under the BPCIA patent dance, where applicable.
- Patent-infringement litigation under the BPCIA framework.
- FDA review of analytical, pharmacokinetic, immunogenicity, and clinical evidence.
- Approval subject to reference-product exclusivity and patent outcomes.
- Commercial launch after applicable notice and legal barriers.
As of the public regulatory landscape through 2024, no FDA-approved biosimilar to eftrenonacog alfa had materially changed the U.S. market. The lack of a biosimilar does not eliminate future entry risk. It reflects the complexity of the product, the limited size of the hemophilia B market, manufacturing requirements, and the commercial cost of conducting a biosimilar development program.
How strong is the Alprolix patent estate?
The estate is commercially strong but time-limited.
Strengths
- Fc-fusion architecture creates a differentiated biologic profile.
- Manufacturing complexity raises the cost of biosimilar development.
- Chronic use produces meaningful switching friction.
- Product-specific clinical experience supports physician retention.
- Multiple patent categories may extend protection beyond a single composition claim.
- Sanofi has global regulatory and commercial resources.
Weaknesses
- The original product has been marketed since 2014.
- Regulatory exclusivity approaches its principal 2026 milestone.
- Competing extended-half-life factor IX products are established.
- Gene therapy creates a non-replacement alternative.
- Some process and platform patents may expire before molecule-specific rights.
- Hemophilia B is a relatively small patient population for biosimilar economics.
The estate is strongest against rapid substitution and weakest against gradual share migration. A competitor does not need to invalidate every Alprolix patent to erode its economics. A differentiated factor IX product, gene therapy, or nonfactor prophylaxis can compete without directly copying the Fc-fusion molecule.
What generic and biosimilar launch risks exist?
Traditional generic launch risk is low because Alprolix is a biologic. Biosimilar risk is more relevant, but market entry would probably be gradual.
Near-term launch scenarios
| Scenario |
Timing |
Market effect |
| No biosimilar launch |
Before and shortly after 2026 |
Continued premium pricing and stable recurring revenue |
| First biosimilar approval |
After reference-product exclusivity and patent resolution |
Limited initial discounting and payer experimentation |
| Multiple biosimilars |
Later market phase |
Greater price pressure and formulary competition |
| Gene therapy expansion |
Ongoing |
Reduced new-patient starts on lifelong factor therapy |
| Nonfactor adoption |
Ongoing |
Selective displacement in prophylaxis patients |
Payers may favor biosimilars for stable patients if discounts are substantial. Physicians and patients may resist switching when bleed control is established, particularly in pediatric care or in patients with complex dosing histories. The commercial result is more likely to be price compression and lower new-patient share than an immediate collapse in total revenue.
How does gene therapy affect Alprolix demand?
Hemgenix, an adeno-associated virus gene therapy for adults with hemophilia B who use factor IX prophylaxis or have current or historical life-threatening bleeding, was approved by FDA in November 2022. It introduced a one-time-treatment alternative to chronic factor replacement. (FDA, 2022)
The impact on Alprolix is constrained by:
- Patient eligibility.
- AAV antibody status.
- Liver health.
- Durability of factor expression.
- One-time treatment cost.
- Payer authorization.
- Patient willingness to accept gene therapy risk.
- Need for continued monitoring.
Gene therapy has its greatest effect on future patient starts and treatment decisions in eligible adults. It is less likely to eliminate the factor IX market because some patients will remain ineligible, decline treatment, lose expression over time, or require factor replacement for breakthrough bleeding or procedures.
What licensing deals affect eftrenonacog alfa?
The product originated from collaboration among Biogen, Sobi, and Sanofi-linked commercial rights. Sobi has held important rights for Alprolix in certain territories, while Sanofi obtained global strategic control through the Bioverativ acquisition. The transaction consolidated ownership of Bioverativ's hemophilia assets within Sanofi, subject to existing regional arrangements. (Sanofi, 2018; Sobi, 2024)
Licensing and regional-rights arrangements matter because Alprolix revenue is split by geography and partner economics. They also affect manufacturing responsibility, regulatory submissions, pricing authority, and the allocation of biosimilar litigation rights.
What is the geographic market outlook?
The United States remains the most commercially important market because of diagnosis rates, specialist treatment centers, insurance coverage, and established use of prophylaxis. Europe has strong hemophilia infrastructure but more aggressive tendering and pricing controls. Emerging markets offer patient-growth potential but face diagnosis, reimbursement, and infusion-access constraints.
| Region |
Market outlook |
| United States |
Highest realized price; rising gene-therapy and payer pressure |
| Western Europe |
Stable specialist demand; tender and reimbursement constraints |
| Japan |
Mature hemophilia market with regulatory and pricing controls |
| China |
Diagnosis and access expansion; lower realized pricing |
| Latin America |
Uneven public-sector access and procurement dependence |
| Middle East and Africa |
Significant treatment gap but infrastructure limitations |
Sanofi's distribution capabilities support international access, but the commercial opportunity is not uniform. The largest volume growth may come from improving diagnosis and treatment access, while the largest margin pressure is likely in mature reimbursed markets.
What are the manufacturing and intellectual-property barriers?
Alprolix requires mammalian-cell recombinant production, purification, viral-clearance controls, analytical comparability, and specialized fill-finish operations. A biosimilar developer must demonstrate similarity across structure, glycosylation, Fc function, potency, impurities, stability, and immunogenicity.
Manufacturing barriers include:
- Cell-line and process development.
- Control of product-related variants.
- Consistent factor IX activity.
- Fc-fusion characterization.
- Viral safety validation.
- Scale-up and batch reproducibility.
- Cold-chain distribution.
- Clinical and postmarketing pharmacovigilance.
These barriers do not make entry impossible. They make entry capital-intensive and reduce the number of economically viable competitors.
Key Takeaways
- Eftrenonacog alfa, marketed as Alprolix, is a long-acting recombinant factor IX Fc fusion protein approved in the United States in 2014.
- Sanofi acquired the product through its $11.6 billion Bioverativ transaction in 2018.
- The product has recurring chronic-treatment revenue but is transitioning from growth to franchise defense.
- U.S. biologic reference-product exclusivity reaches its principal 12-year milestone in March 2026.
- Alprolix is governed by the Purple Book and BPCIA framework, not the conventional Orange Book and Paragraph IV process.
- Direct biosimilar risk is limited in the near term by biologic complexity, manufacturing requirements, and market size.
- Gene therapy and nonfactor prophylaxis create greater strategic pressure than traditional generic substitution.
- Patent strength depends on the combined molecule, formulation, manufacturing, method-of-use, and platform estate.
- The most likely commercial erosion pattern is gradual loss of new-patient starts, selective switching, and payer-driven price pressure.
FAQs
Is Alprolix the same as recombinant factor IX?
No. Alprolix is recombinant factor IX modified by fusion to an IgG1 Fc domain. Conventional products such as BeneFIX contain recombinant factor IX without the same Fc-fusion architecture.
Is Alprolix a biosimilar?
No. Alprolix is the reference biologic for eftrenonacog alfa. A biosimilar would need to establish high similarity to Alprolix through the FDA's section 351(k) pathway.
Can Alprolix be replaced by Hemgenix?
Some eligible adults may transition from factor IX prophylaxis to Hemgenix, but the therapies are not interchangeable for every patient. Eligibility, AAV antibody status, liver condition, durability, and payer approval affect the decision.
Does Alprolix have an Orange Book patent listing?
No conventional Orange Book listing governs Alprolix because it is a biologic. The relevant U.S. framework is the Purple Book, the BLA record, BPCIA procedures, and separately identified patent rights.
What is the biggest long-term risk to Alprolix revenue?
The largest long-term risk is cumulative displacement from gene therapy, newer factor IX products, nonfactor prophylaxis, and biosimilar competition after regulatory exclusivity and relevant patent barriers decline.
References
-
Bioverativ Inc. (2018). Annual report and Form 10-K for the year ended December 31, 2017. U.S. Securities and Exchange Commission.
-
Food and Drug Administration. (2014). FDA approves Alprolix to prevent and treat bleeding in people with hemophilia B. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2022). FDA approves first gene therapy for adults with hemophilia B. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024a). Alprolix prescribing information. U.S. Department of Health and Human Services.
-
Sanofi. (2018). Sanofi to acquire Bioverativ for $105 per share in cash. Sanofi.
-
Sanofi. (2024). Universal registration document and annual financial report 2023. Sanofi.
-
Sobi. (2024). Annual and sustainability report 2023. Swedish Orphan Biovitrum AB.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.
